ADMA Biologics
ADMA
357 hedge funds and large institutions have $1.91B invested in ADMA Biologics in 2026 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 136 increasing their positions, 109 reducing their positions, and 61 closing their positions.
129% more call options, than puts
Call options by funds: $67.1M | Put options by funds: $29.3M
25% more repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 109
15% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 61
0% more funds holding
Funds holding: 356 → 357 (+1)
3.6% less ownership
Funds ownership: 92.59% → 88.99% (-3.6%)
52% less capital invested
Capital invested by funds: $4.02B → $1.91B (-$2.1B)
75% less funds holding in top 10
Funds holding in top 10: 8 → 2 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$71.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$67.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$45.7M |
| 4 |
Millennium Management
New York
|
+$43.6M |
| 5 |
Jane Street
New York
|
+$40.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SHCM
Sachem Head Capital Management
New York
|
-$207M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$128M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$121M |
| 4 |
Janus Henderson Group
London,
|
-$60.6M |
| 5 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$57.3M |
ADMA Hedge Fund Activity: Q1 2026 in Review
357 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2026, worth a combined $1.91B — down 52% from $4.02B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new ADMA positions and 61 closed out — a net gain of 9 holders — while 136 added to existing stakes and 109 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $71.9M. The largest seller was Sachem Head Capital Management, exiting entirely with an estimated $207M sold.
- 357 institutional investors held ADMA Biologics (ADMA) as of Q1 2026, up from 356 in Q4 2025.
- Funds reported $1.91B of ADMA Biologics stock for Q1 2026, down 52% quarter-over-quarter.
- 70 funds opened new ADMA Biologics positions in Q1 2026 and 61 closed out, a net change of +9 holders.
- The largest ADMA Biologics buyer in Q1 2026 was Capital Research Global Investors, an estimated $71.9M added.
- The largest ADMA Biologics seller in Q1 2026 was Sachem Head Capital Management, an estimated $207M sold.
Based on aggregated 13F filings for Q1 2026.